Arthritis, psoriatic

This study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. About 1560 adults who finished an earlier study will receive the drug as a shot under the skin. Researchers will track side effects and how well the drug c…

This phase 4 trial tests whether guselkumab (TREMFYA) can reduce spine-related symptoms in people with active psoriatic arthritis who have not used biologic drugs before. About 411 participants will receive either guselkumab or a placebo as a shot under the skin. The main goal is…

This phase 3 trial tested guselkumab, a biologic drug given as a shot, in over 1,000 people with active psoriatic arthritis who had not responded well to other treatments. The goal was to see if it reduces symptoms like joint pain and swelling and slows joint damage seen on X-ray…

This study tests an experimental drug called JNJ-77242113 (icotrokinra) against a placebo in 552 adults with active psoriatic arthritis who have not tried biologic treatments before. The main goal is to see if the drug reduces joint swelling and tenderness after 16 weeks. Partici…

This study follows 159 children aged 2 to 17 who have already completed a prior ustekinumab study for Crohn's disease, ulcerative colitis, or psoriatic arthritis. The goal is to collect long-term safety data by monitoring side effects, lab results, and injection-site reactions. P…

This study tests a drug called sonelokimab in 960 adults with active psoriatic arthritis who have not used biologic treatments before. The goal is to see if it reduces joint pain and swelling better than a placebo. Participants receive injections over several months, and research…

This study follows over 1,300 people with psoriatic arthritis who are starting either guselkumab (Tremfya) or an IL-17 inhibitor as part of their routine care. Researchers will track how long patients continue each treatment and monitor joint swelling and tenderness. The goal is …